NASDAQ:IMVT

Immunovant (IMVT) Stock Forecast, Price & News

$20.91

-0.34 (-1.60%)

(As of 11:01 AM ET)

Compare

Today's Range: $20.80
▼
$21.51
50-Day Range: $14.20
▼
$23.75
52-Week Range: $3.14
▼
$24.18

Volume: 112,749 shs
Average Volume: 1.02 million shs
Market Capitalization: $2.73 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.77

Immunovant MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.91 Rating Score
Upside/Downside: 16.6% Upside
$24.77 Price Target
Short Interest: Bearish
8.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.08
Based on 7 Articles This Week
Insider Trading: Selling Shares
$135,979 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.76) to ($1.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

909th out of 981 stocks

Biological Products, Except Diagnostic Industry

156th out of 165 stocks

2.5

Analyst's Opinion

Consensus Rating
Immunovant has received a consensus rating of Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.77, Immunovant has a forecasted upside of 16.6% from its current price of $21.25.
Amount of Analyst Coverage
Immunovant has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.37% of the float of Immunovant has been sold short.
Short Interest Ratio / Days to Cover
Immunovant has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Immunovant has recently decreased by 4.86%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Immunovant does not currently pay a dividend.
Dividend Growth
Immunovant does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMVT.

3.4

News and Social Media Coverage

News Sentiment
Immunovant has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Immunovant this week, compared to 4 articles on an average week.
Search Interest
Only 8 people have searched for IMVT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
1 people have added Immunovant to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $135,979.00 in company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Immunovant is held by insiders.
Percentage Held by Institutions
Only 32.77% of the stock of Immunovant is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunovant are expected to decrease in the coming year, from ($1.76) to ($1.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunovant is -12.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunovant is -12.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunovant has a P/B Ratio of 7.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Stock News Headlines

June 8, 2023 | americanbankingnews.com

Immunovant, Inc. to Post Q1 2024 Earnings of ($0.46) Per Share, Zacks Research Forecasts (NASDAQ:IMVT)

May 29, 2023 | americanbankingnews.com

Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Brokerages

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 26, 2023 | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Price Target Raised to $32.00 at Guggenheim